Centre Hospitalier Du Mans
Le Mans, 72000, France
Location status: Recruiting
Location contact
Christelle JADEAU
CONTACT
Claire NEVEUX-BRECHETEAU, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT04800276
The prevalence of peripheral arterial disease is 12.2% in France. Intermittent claudication is the most common symtom of this disease. During physical exercise, such as walking, blood oxygen (O2) requirements increase. The development of atherosclerosis in the lower limbs, causes narrowing of the arteries and limits the increase in blood flow required for muscular effort. Patients then experience muscle pain, the intensity of which gradually increases until it forces them to stop. After stopping, the pain subsides and disappears in less than 10 minutes.
The location of the pain (calves and/or thighs and/or buttocks) is related to the location of the ischemia (distal in the calf, proximal in the thigh or buttock, or proximo-distal if several locations). This can have different consequences on the biomechanical parameters of walking and muscle activity. To date, the impact of this localization on physical capacity has never been studied.
These limitations are very disabling and impact the quality of life of patients.
In addition, poor lower limb performance is associated with higher mortality. Reducing symptomatology and improving functional abilities is therefore a major issue in patients with peripheral arterial disease. This can be achieved through the practice of an Adapted Physical Activity, an essential recommendation in the care of patients with peripheral arterial disease.
Our main hypothesis is that the physical activity rehabilitation protocol "Activ'AO" will improve the functional capacities of patients with peripheral arterial disease who have followed the program with the localization of ischemia with a greater consideration than in patients in the group following a "standard" APA protocol. Improvements in functional abilities (such as walking) will lead to improvements in quality of life.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Le Mans, 72000, France
Location status: Recruiting
Christelle JADEAU
CONTACT
Claire NEVEUX-BRECHETEAU, MD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
muscle strengthening targeted on ischemic areas
global muscle strenghtening
Time frame: 12 weeks after inclusion
The efficacity of Adapted Physical Activity was assessed by measure of maximum walking distance
Time frame: 12 weeks after inclusion
The efficacity of Adapted Physical Activity was assessed by measure of walking speed with actimeter
Time frame: 12 weeks after inclusion
The efficacity of Adapted Physical Activity was assessed by measure of balance static with stabilometry Platform.
Time frame: At week 12
Assess quality of life with the "Vascular Quality of Life" questionnaire, and physical activity levels with the "Global Physical Activity Questionnaire".
Time frame: 12 weeks after inclusion
The efficacy of Adapted Physical Activity on strength capacities is measured using grip strength, dynamometers and the chair lift test
Time frame: 12 weeks after inclusion
The efficacy of Adapted Physical Activity on neuromuscular activity is measured using surface electromyography
Contact information is provided by the study sponsor or research team.
Christelle JADEAU
CONTACT
Karine MONTACLAIR
CONTACT
Centre Hospitalier le Mans
Other
Adapted Physical Activity in Patients With Lower Limb Peripheral Arterial Disease (ACTIV'AO)
Acronym: ACTIV'AO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07144150
Arterial Occlusive Diseases, Arteriosclerosis
New Haven, Connecticut, United States
View Trial DetailsNCT07223593
Arterial Occlusive Diseases, Arteriosclerosis
Birmingham, Alabama, United States
View Trial DetailsNCT07076082
Arterial Occlusive Diseases, Arteriosclerosis
Detroit, Michigan, United States
View Trial DetailsNCT07353905
Arterial Occlusive Diseases, Arteriosclerosis
Dallas, Texas, United States
View Trial Details